Research programme: human histone methyltransferase inhibitors - Epizyme/GlaxoSmithKline

Drug Profile

Research programme: human histone methyltransferase inhibitors - Epizyme/GlaxoSmithKline

Alternative Names: DOT1L inhibitors - Epizyme; EPZ 01566; EPZ 015666; HDAC inhibitors - Epizyme; HMT inhibitors - Epizyme; HMT3 inhibitors - Epizyme; WHSC1 inhibitors - Epizyme

Latest Information Update: 10 Dec 2014

Price : $50

At a glance

  • Originator Epizyme
  • Class Small molecules
  • Mechanism of Action DNA methylation inhibitors; Histone deacetylase inhibitors; Histone methyltransferase inhibitors; Protein methyltransferase modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Haematological malignancies; Leukaemia; Mantle-cell lymphoma; Non-Hodgkin's lymphoma

Most Recent Events

  • 08 Dec 2014 Pharmacodynamics data from a preclinical trial in Mantle cell lymphoma released by Epizyme
  • 28 Oct 2014 Preclinical development is ongoing in USA
  • 14 Mar 2012 Epizyme receives funds from The Leukaemia & Lymphoma Society for DOT1L-targeted histone methyltransferase inhibitor development in Leukaemia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top